ATE192932T1 - Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff - Google Patents

Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff

Info

Publication number
ATE192932T1
ATE192932T1 AT94306351T AT94306351T ATE192932T1 AT E192932 T1 ATE192932 T1 AT E192932T1 AT 94306351 T AT94306351 T AT 94306351T AT 94306351 T AT94306351 T AT 94306351T AT E192932 T1 ATE192932 T1 AT E192932T1
Authority
AT
Austria
Prior art keywords
substance
antibacterial
antiulcer
present
formulation
Prior art date
Application number
AT94306351T
Other languages
English (en)
Inventor
Yohko Akiyama
Masafumi Nakao
Naoki Nagahara
Susumu Iwasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE192932T1 publication Critical patent/ATE192932T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT94306351T 1993-09-09 1994-08-30 Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff ATE192932T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22470793 1993-09-09

Publications (1)

Publication Number Publication Date
ATE192932T1 true ATE192932T1 (de) 2000-06-15

Family

ID=16817987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94306351T ATE192932T1 (de) 1993-09-09 1994-08-30 Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff

Country Status (8)

Country Link
US (3) US5948773A (de)
EP (2) EP0642797B1 (de)
KR (1) KR100324781B1 (de)
CN (1) CN1051922C (de)
AT (1) ATE192932T1 (de)
CA (1) CA2131569A1 (de)
DE (1) DE69424487T2 (de)
ES (1) ES2145102T3 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505032D0 (en) * 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
RU2173147C2 (ru) * 1996-05-09 2001-09-10 Санкио Компани Лимитед Применение производных 1-метилкарбопенема, антибактериальная в отношении helicobacter pylori композиция, содержащая в качестве активного ингредиента 1-метилкарбопенемовые производные и способ профилактики или лечения инфекционных заболеваний
DE19624201A1 (de) * 1996-06-18 1998-01-08 Bayer Ag Verwendung von Acylureidoacetamidopenicillinen
ATE286715T1 (de) 1997-03-25 2005-01-15 Takeda Chemical Industries Ltd Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung
WO1998042323A1 (en) * 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Stabilized urease inhibitor
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
DK1037607T3 (da) * 1997-12-08 2004-06-21 Altana Pharma Ag Hidtil ukendt suppositoriumsform, der omfatter en syrelabil aktiv forbindelse
KR100572090B1 (ko) * 1998-02-24 2006-04-17 액티브 바이오틱스 인코포레이티드 상승작용이 있는 항균제 조성물, 그것을 함유하는 의약 및 소화기질환 치료제, 그들의 제조 방법, 및 그에 관련된 제제
HUP0101248A2 (hu) 1998-03-20 2001-08-28 Kowa Co., Ltd. Gyomor- és/vagy nyombél-adhezív gyógyászati készítmények
PL360916A1 (en) * 1999-03-29 2004-09-20 Wyeth Coating system
YU86001A (sh) * 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
CA2381860C (en) 1999-08-26 2009-11-24 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU5424500A (en) 2000-02-24 2001-09-03 Kopran Res Lab Ltd Orally administrable acid stable anti-ulcer benzimidazole derivatives
WO2002011726A1 (en) * 2000-08-08 2002-02-14 Daiichi Pharmaceutical Co., Ltd. Highly absorbable solid preparation
US6409800B1 (en) 2000-08-28 2002-06-25 The Boc Group, Inc. Temperature swing adsorption process
EP1210950B1 (de) * 2000-12-04 2005-10-19 New Pharma Research Sweden AB Zusammensetzung gegen Coccidiose
US20030017133A1 (en) * 2001-06-15 2003-01-23 Wyeth (Formerly American Home Products Corporation) Mucoadhesive composition
ES2392960T3 (es) 2001-10-17 2012-12-17 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
ES2384208T3 (es) 2001-11-01 2012-07-02 Spectrum Pharmaceuticals, Inc. Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga.
US20040028744A1 (en) * 2002-06-17 2004-02-12 Sauwaluxana Tongaree Mucoadhesive composition
TWI336260B (en) * 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
KR100474920B1 (ko) * 2002-12-05 2005-03-10 엘지전자 주식회사 세탁기의 운전제어방법
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
WO2004075881A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
US7085154B2 (en) * 2003-06-03 2006-08-01 Samsung Electronics Co., Ltd. Device and method for pulse width control in a phase change memory device
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005027876A1 (en) * 2003-08-28 2005-03-31 Ranbaxy Laboratories Limited Pharmaceutical compositions of benzimidazole and processes for their preparation
AU2004290983A1 (en) * 2003-11-19 2005-06-02 Vecta Ltd. Methods and compositions for the treatment of Helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
EP1718303A4 (de) * 2004-02-10 2010-09-01 Santarus Inc Kombination eines protonenpumpenhemmers, puffermittels und einem nichtsteroidalen entzündungshemmenden mittel
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ATE533757T1 (de) * 2006-03-10 2011-12-15 Arigen Pharmaceuticals Inc Neues pyridinderivat mit wirkung gegen helicobacter pylori
JP2009539866A (ja) * 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
EP2172203A1 (de) * 2008-09-17 2010-04-07 Giuliani S.P.A. Pharmazeutisches Zusammensetzung zur Behandlung von Magen-Darm-Reizungsstörungen
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EP3824296A4 (de) 2018-07-20 2022-04-27 Lipocine Inc. Lebererkrankung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
EP0403048A3 (de) * 1989-06-14 1991-01-30 Warner-Lambert Company Medizinische Sucralfat enthaltende Zusammensetzungen und Verfahren zur Herstellung
CA2087596A1 (en) * 1990-07-20 1992-01-21 John Rhodes Products and processes for the treatment of the alimentary canal
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
ES2169022T3 (es) * 1990-09-14 2002-07-01 Byk Gulden Lomberg Chem Fab Utilizacion de derivados de (piridil-metil-sulfinil)-1-h-bencimidazol para el tratamiento de enfermedades provocadas por helicobacter.
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
SE9201930D0 (sv) * 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment

Also Published As

Publication number Publication date
CN1051922C (zh) 2000-05-03
ES2145102T3 (es) 2000-07-01
CA2131569A1 (en) 1995-03-10
EP0995447A1 (de) 2000-04-26
KR950007850A (ko) 1995-04-15
EP0642797A1 (de) 1995-03-15
DE69424487T2 (de) 2001-01-18
KR100324781B1 (ko) 2002-09-19
US20010027192A1 (en) 2001-10-04
US5948773A (en) 1999-09-07
EP0642797B1 (de) 2000-05-17
US6319904B1 (en) 2001-11-20
DE69424487D1 (de) 2000-06-21
CN1105855A (zh) 1995-08-02

Similar Documents

Publication Publication Date Title
ATE192932T1 (de) Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
HU9203623D0 (en) High-dosed forms of collagenase for local applications
PL299870A1 (en) 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, crystalline hydrate of 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, method of obtaining these compounds, pharmaceutical preparation and method of fighting against bacteriae
DK415689A (da) Farmaceutiske midler
IS5577A (is) Omeprazól örkorn vernduð gegn magasýrum, framleiðsluferli og lyfjasamsetningar
HK78197A (en) Medicaments for treating gastrointestinal disorders
IT1275816B1 (it) Composizioni farmaceutiche solide per uso vaginale
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
IL95391A0 (en) Substituted n-(quinolin-2-yl-methoxy)benzyl-sulphonyl-ureas,their preparation and pharmaceutical compositions containing them
AU773079C (en) Immunopotentiating compositions
CA2252399A1 (en) Composition for demonstrating the presence of ammonia in exhaled air
GB2021409A (en) Pharmaceutical composition
ES2054089T3 (es) Formulaciones orales liquidas.
HUP9902559A2 (hu) Paracetamolt és drotavenint tartalmazó gyógyszerkészítmény és eljárás előállítására
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
WO1997025032A3 (en) Monoglyceride compositions and their use against helicobacter
TH16891A (th) สูตรผสมที่ประกอบด้วยสารต่อต้านแบคทีเรียและสารต่อต้านแผลอัลเซอร์
IE811773L (en) Pharmaceutical comosition containing imidazolesalicylate
DK39891A (da) N-(2-aminoethyl)-pyridin-2-carboxamid og farmaceutisk anvendelige syreadditionssalte deraf til anvendelse som terapeutisk virksomme stoffer samt laegemidler indeholdende disse forbindelser
JPS5210425A (en) An antibiotic pharmaceutical with low reaction
UA28457A (uk) Лікарський засіб "діпрацетам", що має знеболювальну та жарознижувальну дію та спосіб його одержання
ES8707665A3 (es) Procedimiento de produccion de preparados farmaceuticos conteniendo al menos una materia activa farmaceutica,especialmente una materia activa insoluble o dificil o lentamente soluble.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties